Bio-Rad Laboratories Inc (BIO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bio-Rad Laboratories Inc (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010870
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Bio-Rad Laboratories Inc (Bio-Rad) develops and manufactures specialty chemicals for use in biochemical, pharmaceutical and other life science research applications. The company offers a comprehensive range of reagents, apparatus, laboratory instruments, test systems, informatics systems, test kits and specialized quality controls. It offers these products to hospitals, clinical laboratories, universities, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, and food producers. The company offers its products and services to its clients though a global network of subsidiaries. The company operates in North America, Europe, Asia, the Middle East and Africa. Bio-Rad is headquartered in California, the US.

Bio-Rad Laboratories Inc (BIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Bio-Rad Laboratories Inc, Medical Devices Deals, 2011 to YTD 2017 10
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
RainDance Technologies Raises US$16.5 Million In Extended Series E Financing 13
RainDance Technologies Raises US$35 Million In Venture Financing 14
RainDance Technologies Raises US$20 Million In Series E Financing 15
GnuBio Raises US$10 Million In Series B Financing 16
GnuBio Secures US$5 Million In Second Closing Of Series A Financing 17
RainDance Technologies Secures US$37.5 Million In Series D Financing 18
Partnerships 19
AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 19
AbD Serotec Enters Into Licensing Agreement With Proteomika 20
Genetic Analysis Enters into Agreement with Bio-Rad Labs 21
Bio-Rad Laboratories Enters into Partnership with Illumina 22
Pacific Biosciences Enters into Co-Development and Co-Marketing Agreement with RainDance Technologies 23
RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 24
RainDance Technologies Enters Into Co-Development Agreement With MLL Munchner Leukamie Labor 25
RainDance Technologies Enters Into Co-Development Agreement With Sony DADC Austria 26
AbD Serotec Enters Into Research Agreement With Dana-Farber Cancer Institute 27
Licensing Agreements 28
Vegenics Enters into Licensing Agreement with Bio-Rad Labs 28
AbD Serotec Amends Licensing Agreement With Merck 29
Asset Transactions 30
Ambry Genetics Acquires ThunderStorm System From RainDance Technologies 30
Acquisition 32
Bio-Rad Labs to Acquire RainDance Technologies 32
Bio-Rad Labs Acquires GnuBio, DNA Sequencing Technology Company 33
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 34
Bio-Rad Labs Acquires QuantaLife For US$162 Million 36
Bio-Rad Labs Acquires Additional 39% Stake In DiaMed Spain For US$3.4 Million 37
Bio-Rad Laboratories Inc – Key Competitors 38
Bio-Rad Laboratories Inc – Key Employees 39
Bio-Rad Laboratories Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 44
Financial Announcements 44
Nov 02, 2017: Bio-Rad Reports Third-Quarter 2017 Financial Results 44
Aug 03, 2017: Bio-Rad Reports Second-Quarter 2017 Financial Results 45
May 04, 2017: Bio-Rad Reports First-Quarter 2017 Financial Results 46
Mar 13, 2017: Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day 47
Feb 23, 2017: VBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 48
Feb 23, 2017: Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 50
Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent 52
Aug 03, 2016: Bio-Rad Reports Second-Quarter 2016 Financial Results 53
May 05, 2016: Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent 54
Feb 25, 2016: Bio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial Results 55
Corporate Communications 57
Mar 13, 2017: Bio-Rad Intends to Propose Three New Independent Directors 57
Product News 58
Dec 04, 2017: Bio-Rad Releases First CE-IVD Digital PCR Test for Monitoring Chronic Myeloid Leukemia Response to Therapy 58
Jul 19, 2016: Bio-Rad Launches Clarity Max Western ECL Substrate 59
Jul 11, 2016: Bio-Rad Launches ddPCR CHO and E. coli Kits for Direct Quantification of Residual Host Cell DNA 60
Jun 09, 2016: Bio-Rad Laboratories released ChromLab Software Version 4.0 61
May 01, 2017: Bio-Rad Expands Its Multiplex Immunoassays with the Launch of Bio-Plex Pro Human Apolipoprotein Panel 62
Apr 19, 2017: Bio-Rad Releases Labeled Antibodies for Fluorescent Multiplex Detection of Proteins in Western Blots 63
Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bio-Rad Laboratories Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Bio-Rad Laboratories Inc, Medical Devices Deals, 2011 to YTD 2017 10
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
RainDance Technologies Raises US$16.5 Million In Extended Series E Financing 13
RainDance Technologies Raises US$35 Million In Venture Financing 14
RainDance Technologies Raises US$20 Million In Series E Financing 15
GnuBio Raises US$10 Million In Series B Financing 16
GnuBio Secures US$5 Million In Second Closing Of Series A Financing 17
RainDance Technologies Secures US$37.5 Million In Series D Financing 18
AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 19
AbD Serotec Enters Into Licensing Agreement With Proteomika 20
Genetic Analysis Enters into Agreement with Bio-Rad Labs 21
Bio-Rad Laboratories Enters into Partnership with Illumina 22
Pacific Biosciences Enters into Co-Development and Co-Marketing Agreement with RainDance Technologies 23
RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 24
RainDance Technologies Enters Into Co-Development Agreement With MLL Munchner Leukamie Labor 25
RainDance Technologies Enters Into Co-Development Agreement With Sony DADC Austria 26
AbD Serotec Enters Into Research Agreement With Dana-Farber Cancer Institute 27
Vegenics Enters into Licensing Agreement with Bio-Rad Labs 28
AbD Serotec Amends Licensing Agreement With Merck 29
Ambry Genetics Acquires ThunderStorm System From RainDance Technologies 30
Bio-Rad Labs to Acquire RainDance Technologies 32
Bio-Rad Labs Acquires GnuBio, DNA Sequencing Technology Company 33
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 34
Bio-Rad Labs Acquires QuantaLife For US$162 Million 36
Bio-Rad Labs Acquires Additional 39% Stake In DiaMed Spain For US$3.4 Million 37
Bio-Rad Laboratories Inc, Key Competitors 38
Bio-Rad Laboratories Inc, Key Employees 39
Bio-Rad Laboratories Inc, Other Locations 40
Bio-Rad Laboratories Inc, Subsidiaries 41

★調査レポート[Bio-Rad Laboratories Inc (BIO)-製薬・医療分野:企業M&A・提携分析] (コード:DATA8010870)販売に関する免責事項を必ずご確認ください。
★調査レポート[Bio-Rad Laboratories Inc (BIO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆